# Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242

> **NCT02824666** · PHASE1 · COMPLETED · sponsor: **Braeburn Pharmaceuticals** · enrollment: 7 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ATI-9242
- **RADIATION:** [18F]Fallypride Imaging

## Key facts

- **NCT ID:** NCT02824666
- **Lead sponsor:** Braeburn Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-20
- **Primary completion:** 2016-09-06
- **Final completion:** 2016-11-08
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2017-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02824666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02824666, "Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02824666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*